NCT00053326View on ClinicalTrials.gov

Fenretinide in Treating Children With Recurrent or Resistant Neuroblastoma

PHASE2CompletedINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

May 31, 2003

Primary Completion Date

March 31, 2006

Conditions
Recurrent Neuroblastoma
Interventions
DRUG

fenretinide

Given orally

OTHER

pharmacological study

Optional correlative studies

Trial Locations (1)

91006-3776

Children's Oncology Group, Arcadia

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00053326 - Fenretinide in Treating Children With Recurrent or Resistant Neuroblastoma | Biotech Hunter | Biotech Hunter